MedTrace Logo

Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma

NCT03322917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-12-04

No results posted yet for this study

Summary

To evaluate the efficacy of autologous platelet-rich plasma eye drops (E-PRP) for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK).

Conditions

  • Dry Eye After LASIK-Laser in Situ Keratomileusis

Interventions

BIOLOGICAL

PRP autologous

Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks

Sponsors & Collaborators

  • Vissum, Instituto Oftalmológico de Alicante

    lead OTHER

Principal Investigators

  • JORGE L ALIO, DR. · Vissum, Instituto Oftalmológico de Alicante

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-01
Primary Completion
2013-01-17
Completion
2013-01-17

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322917 on ClinicalTrials.gov